Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine,
and prednisolone, work in different ways to stop the growth of cancer cells, either by
killing the cells or stopping them from dividing. Bortezomib may stop the growth of cancer
cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy
together with bortezomib may kill more cancer cells. It is not yet known whether combination
chemotherapy is more effective with or without bortezomib in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial is studying combination chemotherapy and bortezomib
to see how well they work compared with combination chemotherapy alone in treating patients
with relapsed or refractory mantle cell lymphoma. Combination chemotherapy alone (Arm I) has
been discontinued April 2012 on recommendation of the DMC.
Phase:
Phase 2
Details
Lead Sponsor:
Plymouth Hospitals NHS Trust University Hospital Plymouth NHS Trust